0.6506
Precedente Chiudi:
$0.7371
Aprire:
$0.7161
Volume 24 ore:
1.46M
Relative Volume:
1.15
Capitalizzazione di mercato:
$64.53M
Reddito:
$153.73M
Utile/perdita netta:
$-106.79M
Rapporto P/E:
-0.3655
EPS:
-1.78
Flusso di cassa netto:
$-115.93M
1 W Prestazione:
-15.54%
1M Prestazione:
-59.08%
6M Prestazione:
-81.20%
1 anno Prestazione:
-88.48%
Sutro Biopharma Inc Stock (STRO) Company Profile
Nome
Sutro Biopharma Inc
Settore
Industria
Telefono
650-392-8412
Indirizzo
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Confronta STRO con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
STRO
Sutro Biopharma Inc
|
0.6506 | 64.53M | 153.73M | -106.79M | -115.93M | -1.78 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
2025-03-14 | Downgrade | BofA Securities | Buy → Underperform |
2025-03-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
2025-03-14 | Downgrade | Wedbush | Outperform → Neutral |
2024-05-08 | Iniziato | BofA Securities | Buy |
2023-11-09 | Iniziato | Deutsche Bank | Buy |
2023-10-06 | Iniziato | Oppenheimer | Outperform |
2023-03-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2022-08-18 | Ripresa | Wells Fargo | Overweight |
2021-06-18 | Iniziato | H.C. Wainwright | Buy |
2020-12-03 | Iniziato | Stifel | Buy |
2020-09-02 | Iniziato | Jefferies | Buy |
2020-07-16 | Iniziato | Wells Fargo | Overweight |
2020-01-13 | Iniziato | SunTrust | Buy |
2019-10-07 | Iniziato | BTIG Research | Buy |
2019-07-18 | Iniziato | Deutsche Bank | Buy |
2019-04-29 | Iniziato | H.C. Wainwright | Buy |
2018-10-22 | Iniziato | JMP Securities | Mkt Outperform |
2018-10-22 | Iniziato | Piper Jaffray | Overweight |
2018-10-22 | Iniziato | Wedbush | Outperform |
Mostra tutto
Sutro Biopharma Inc Borsa (STRO) Ultime notizie
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Sutro Biopharma stock hits 52-week low at $0.76 amid sharp decline - Investing.com Australia
Sutro Biopharma stock hits 52-week low at $0.76 amid sharp decline By Investing.com - Investing.com South Africa
Connor Clark & Lunn Investment Management Ltd. Sells 110,734 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma lays off dozens of employees in ‘strategic portfolio review’ - MSN
HC Wainwright Expects Stronger Earnings for Sutro Biopharma - Defense World
Bay Area biotech company laying off 90% of staff as CEO leaves - San Francisco Chronicle
The Escalator: Stoke Therapeutics, Merck, Sutro Biopharma and more - MM+M Online
Sutro Biopharma rises after market hours on portfolio review, restructuring - MSN
Sutro Biopharma’s (STRO) “Neutral” Rating Reaffirmed at HC Wainwright - Defense World
Sutro Biopharma stock rating downgraded at H.C. Wainwright By Investing.com - Investing.com Canada
This Li Auto Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
HC Wainwright Downgrades Sutro Biopharma to Neutral From Buy, Price Target is $2 -March 17, 2025 at 08:33 am EDT - Marketscreener.com
Oppenheimer Downgrades Sutro Biopharma to Market Perform From Outperform -March 17, 2025 at 07:57 am EDT - Marketscreener.com
Deutsche Bank Adjusts Sutro Biopharma Price Target to $5 From $10, Maintains Buy Rating - Marketscreener.com
Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift By Investing.com - Investing.com South Africa
Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift - Investing.com
Sutro Biopharma (NASDAQ:STRO) Cut to Market Perform at Citizens Jmp - Defense World
Array Technologies, Nextracker, Sutro Biopharma - TradingView
Sutro Biopharma (STRO) Expected to Announce Quarterly Earnings on Monday - Defense World
Sutro Biopharma (NASDAQ:STRO) Cut to Neutral at Wedbush - Defense World
Sutro Biopharma (NASDAQ:STRO) Cut to “Underperform” at Bank of America - Defense World
Sutro Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance UK
Sutro Biopharma: Revolutionizing Cancer Treatment with Precision Therapeutics - Apna Kal
Sutro Biopharma Presents Promising Late-Stage Data for Luveltamab Tazevibulin in Platinum-Resistant Ovarian Cancer – Apnakal market - Apna Kal
Sutro Biopharma’s Luvelta Shows Promising Data in Late-Stage Ovarian Cancer Study at SGO 2025 - Apna Kal
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025 - The Manila Times
Sutro's Cancer Drug Doubles Response Rate in Latest Trial, But Faces Uncertain Future - StockTitan
Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler - Yahoo Finance
Bay Area biotech company once worth $2B guts staff, departing execs get $600K - MSN
Sutro Biopharma Prioritizes ADC Programs Amid Financial Shift - TipRanks
Cattle Post Gains on Friday, Helped by Cah Strength - The Globe and Mail
Oppenheimer cuts Sutro Biopharma stock rating to Perform By Investing.com - Investing.com Canada
Oppenheimer cuts Sutro Biopharma stock rating to Perform - Investing.com India
Jefferies cuts Sutro Biopharma target to $8, maintains Buy By Investing.com - Investing.com Canada
Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Strategic Focus and Financial ... - Yahoo Finance
Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Str - GuruFocus.com
Longtime Peninsula biotech to chop half its jobs, CEO exitsSan Francisco Business Times - The Business Journals
Earnings call transcript: Sutro Biopharma Q4 2024 sees stock plunge - Investing.com India
Truist maintains Buy on Sutro Biopharma, removes price target By Investing.com - Investing.com UK
Sutro prioritizes preclinical ADC programs - BioWorld Online
Sutro stock drops as analysts downgrade (STRO:NASDAQ) - Seeking Alpha
Sector Update: Health Care Stocks Higher Premarket Friday -March 14, 2025 at 09:30 am EDT - Marketscreener.com
New ADC focus as Sutro slashes workforce, drops lead drug - The Pharma Letter
This T-Mobile Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - Benzinga
Piper Sandler Downgrades Sutro Biopharma to Neutral From Overweight, Adjusts PT to $2 From $8 - Marketscreener.com
Sutro Cuts Half of Staff, Deprioritizes ADC in Strategic Review - BioSpace
Sutro Biopharma Falls as Company Cuts Workforce, Shifts Focus to ADCs - TradingView
Sutro puts lead ADC on hold, cuts staff and changes CEO - pharmaphorum
Wedbush Downgrades Sutro Biopharma to Neutral From Outperform, Adjusts Price Target to $2 From $8 - Marketscreener.com
Truist Removes $15 Price Target From Sutro Biopharma, Keeps Buy Rating -March 14, 2025 at 06:39 am EDT - Marketscreener.com
Sutro Biopharma Inc Azioni (STRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):